Stock comparison
Haemonetics
IRadimed
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HAE
Haemonetics
Market cap
$2.98B
Sector
Healthcare
IRMD
IRadimed
Market cap
$1.18B
Sector
Healthcare
Overall winner
IRadimed IRMD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HAE | IRMD | Winner |
|---|---|---|---|
| Warren Buffett | 70B | 68B | HAE |
| Benjamin Graham | 85A | 89A | IRMD |
| Philip Fisher | 60C | 92A | IRMD |
| Peter Lynch | 54C | 76B | IRMD |
| Joel Greenblatt | 31F | 65C | IRMD |
| Charlie Munger | 54D | 78B | IRMD |
| Terry Smith | 55D | 75B | IRMD |
Side-by-side metrics
| Metric | HAE | IRMD |
|---|---|---|
| Market cap | $2.98B | $1.18B |
| P/E (TTM) | 24.8x | 50.4x |
| EV/EBIT | 14.1x | 43.4x |
| ROIC (TTM) | 8.37% | 21.38% |
| Gross margin | 55.74% | 76.84% |
| Net margin | 7.29% | 27.36% |
| Revenue CAGR 5y | 7.65% | 18.99% |
| EPS CAGR 5y | 24.62% | 23.53% |
| Debt / Equity | 1.5x | - |
| Dividend yield | 0.0% | 1.33% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HAE leads on
- EV/EBIT14.1xvs 43.4x+67%
- Market cap$2.98Bvs $1.18B+60%
- P/E (TTM)24.8xvs 50.4x+51%
IRMD leads on
- Debt / Equity-vs 1.5x+100%
- Dividend yield1.33%vs 0.0%+100%
- Net margin27.36%vs 7.29%+73%
- ROIC (TTM)21.38%vs 8.37%+61%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.